Human fibroblast activation assay to assess the potential of anti - fibrotic therapeutics.
Newcells’ human primary lung fibroblasts form the basis of our fibroblast-to-myofibroblast (FMT) assay, which allows high throughput in-vitro evaluation of anti-fibrotic therapeutics.
Following injury, the activation and transition of fibroblasts to myofibroblasts, characterized by the incorporation of α-smooth muscle actin (αSMA) into cellular stress fibers, promotes an increased synthesis and deposition of extracellular matrix (ECM) proteins, such as collagen I, to enable wound repair. Exaggerated and prolonged activation of repair mechanisms is known to be a key contributor to lung fibrosis.
Newcells’ FMT-assay replicates these changes in-vitro, mimicking fibroblast activation and matrix deposition.
Available analytical readouts
- Cell number
- Proliferation rates by (cellular EdU incorporation)
- Quantification of collagen I expression and deposition
- Quantification of α-SMA expression
- RNA expression changes
- Quantification of secreted cytokines/biomarkers
Don't miss out on our latest innovations: follow us on Linkedin